a. TP508 (Chrysalin) reverses endothelial dysfunction and increases perfusion and myocardial function in hearts with chronic ischemia. Fossum TW, Olszewska-Pazdrak B, Mertens MM, Makarski LA, Miller MW, Hein TW, Kuo L, Clubb F, Fuller GM, Carney DH. J Cardiovasc Pharmacol Ther. 2008 Sep;13(3):214-25. doi: 10.1177/ 1074248408321468. PMID: 18757834 https://pubmed.ncbi.nlm.nih.gov/18757834/
b. Thrombin fragment (TP508) decreases myocardial infarction and apoptosis after ischemia reperfusion injury. Osipov RM, Bianchi C, Clements RT, Feng J, Liu Y, Xu SH, Robich MP, Wagstaff J, Sellke FW.Ann Thorac Surg. 2009 Mar;87(3):786-93. doi: 10.1016/j.athoracsur.2008.12.021.PMID: 19231390 https://pubmed.ncbi.nlm.nih.gov/19231390/
c. Effect of thrombin fragment (TP508) on myocardial ischemia reperfusion injury in a model of type 1 diabetes mellitus. Chu LM, Osipov RM, Robich MP, Feng J, Sheller MR, Sellke FW.Circulation. 2010 Sep 14;122(11 Suppl):S162-9. doi: 10.1161/CIRCULATIONAHA.109.928374.PMID: 20837908 https://pubmed.ncbi.nlm.nih.gov/20837908/
d. Effect of thrombin fragment (TP508) on myocardial ischemia-reperfusion injury in hypercholesterolemic pigs. Osipov RM, Robich MP, Feng J, Clements RT, Liu Y, Glazer HP, Wagstaff J, Bianchi C, Sellke FW. J Appl Physiol (1985). 2009 Jun;106(6):1993-2001. doi: 10.1152/japplphysiol.00071.2009. Epub 2009 Apr 16.PMID: 19372304 https://pubmed.ncbi.nlm.nih.gov/19372304/
e. Effect of dimerized thrombin fragment TP508 on acute myocardial ischemia reperfusion injury in hypercholesterolemic swine. Oyamada S, Osipov R, Bianchi C, Robich MP, Feng J, Liu Y, Burgess TA, Bell TM, Sheller MR, Sellke FW. J Pharmacol Exp Ther. 2010 Aug;334(2):449-59. doi: 10.1124/jpet.110.166348. Epub 2010 May 11.PMID: 20460385 https://pubmed.ncbi.nlm.nih.gov/20460385/
The TP508 Solution for Vascular Damage
Restoration of Endothelial and Myocardial Function by Injection of TP508
About Us
Chrysalis BioTherapeutics, Inc. is committed to helping improve people’s lives through innovation.
Let’s Socialize
Popular Post
Chrysalis BioTherapeutics, Inc. Announces Collaboration with NIAID to Evaluate Chrysalin® for the Treatment of Cutaneous Radiation Injury
GALVESTON, Texas–(BUSINESS WIRE)–Chrysalis BioTherapeutics, Inc., a clinical stage biopharmaceutical company developing Chrysalin as
Chrysalis BioTherapeutics Selected to Present at Respiratory Innovation Summit
GALVESTON, Texas–(BUSINESS WIRE)–Chrysalis BioTherapeutics today announced it was selected to participate in the
Chrysalis Receives FDA Approval to Initiate Clinical Trials with Chrysalin™ (TP508)
GALVESTON, Texas–(BUSINESS WIRE)–Chrysalis BioTherapeutics, Inc. announced today that the US Food and Drug